Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Structural basis of substrate discrimination and integrin binding by autotaxin.

Authors: Hausmann, J  Kamtekar, S  Christodoulou, E  Day, JE  Wu, T  Fulkerson, Z  Albers, HM  Van Meeteren, LA  Houben, AJ  Van Zeijl, L  Jansen, S  Andries, M  Hall, T  Pegg, LE  Benson, TE  Kasiem, M  Harlos, K  Kooi, CW  Smyth, SS  Ovaa, H  Bollen, M  Morris, AJ  Moolenaar, WH  Perrakis, A 
Citation: Hausmann J, etal., Nat Struct Mol Biol. 2011 Feb;18(2):198-204. doi: 10.1038/nsmb.1980. Epub 2011 Jan 16.
Pubmed: (View Article at PubMed) PMID:21240271
DOI: Full-text: DOI:10.1038/nsmb.1980

Autotaxin (ATX, also known as ectonucleotide pyrophosphatase/phosphodiesterase-2, ENPP2) is a secreted lysophospholipase D that generates the lipid mediator lysophosphatidic acid (LPA), a mitogen and chemoattractant for many cell types. ATX-LPA signaling is involved in various pathologies including tumor progression and inflammation. However, the molecular basis of substrate recognition and catalysis by ATX and the mechanism by which it interacts with target cells are unclear. Here, we present the crystal structure of ATX, alone and in complex with a small-molecule inhibitor. We have identified a hydrophobic lipid-binding pocket and mapped key residues for catalysis and selection between nucleotide and phospholipid substrates. We have shown that ATX interacts with cell-surface integrins through its N-terminal somatomedin B-like domains, using an atypical mechanism. Our results define determinants of substrate discrimination by the ENPP family, suggest how ATX promotes localized LPA signaling and suggest new approaches for targeting ATX with small-molecule therapeutic agents.


Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 8553522
Created: 2014-05-08
Species: All species
Last Modified: 2014-05-08
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.